World Journal of Analytical Chemistry
ISSN (Print): 2333-1178 ISSN (Online): 2333-1283 Website: http://www.sciepub.com/journal/wjac Editor-in-chief: Raluca-Ioana Stefan-van Staden
Open Access
Journal Browser
Go
World Journal of Analytical Chemistry. 2013, 1(4), 80-86
DOI: 10.12691/wjac-1-4-7
Open AccessReview Article

Various Analytical Methods for the Determination of Terazosin in Different Matrices

Alankar Shrivastava1,

1Department of Pharmaceutics, Institute of Biomedical Education and Research, Mangalayatan University, Aligarh, Uttar Pradesh, India

Pub. Date: December 08, 2013

Cite this paper:
Alankar Shrivastava. Various Analytical Methods for the Determination of Terazosin in Different Matrices. World Journal of Analytical Chemistry. 2013; 1(4):80-86. doi: 10.12691/wjac-1-4-7

Abstract

Terazosin is used in men for symptom relief in the case of benign prostatic hyperplasia. This is categorized under the group of alpha one adrenoreceptor blockers. Terazosin is also used in high blood pressure by relaxing blood vessels so that blood can easily pass through. In this systematic review different analytical methods for the determination of terazosin in different matrices are discussed. Overall thirty six different analytical methods for the determination of terazosin were found in literature survey, 12 spectrophotometry, 2 TLC, 2 HPTLC, 16 HPLC and 4 electroanalytical methods were found. Advantages and disadvantages of available methods are also discussed. This review also adds knowledge about the place of terazosin therapy in hypertension or enlarged prostate. This review is useful for the researchers involved in the development of new analytical method or formulation.

Keywords:
Keywords: Terazosin spectrophotometry chromatography HPLC HPTLC method validation

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  Oelke, M., Bachmann, A., Descazeaud, A., Emberton, M., Gravas, S., Michel, M.C., N'dow, J., Nordling, J., de la Rosette, J.J. “EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction” Eur Urol. 2013, Jul 64(1), 118-40.
 
[2]  Barkin, J. “Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management” Can J Urol 2011, 18:14-19.
 
[3]  Shin, I.S., Lee, M.Y., Ha, H.K., Seo, C.S., Shin, H.K., “Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats” BMC Complement Altern Med 2012, 12:48.
 
[4]  Shrivastava, A., Aggrawal, P, “Various Analytical Methodologies for Determination of Selective α1A Receptor Blocker Tamsulosin Hydrochloride and Its Combinations in Different Matrices”. World J Anal Chem, 2013, 1(3), 37-48.
 
[5]  Shrivastava, A., Gupta, V.B, “A Review on Various Analytical Methods on Some Alpha Adrenergic Antagonists” Curr Pharma Anas, 2011, 7, 27-41.
 
[6]  Shrivastava A, Gupta VB, “Various treatment options for benign prostatic hyperplasia: A current update.” J Mid-life health, 2012, 3(1), 10-19.
 
[7]  Hein, P., Michel, C.M. “Signal transduction and regulation: Are all α1-adrenergic receptor subtypes created equal?” Biochem Pharmacol, 2007, 73, 1097-106.
 
[8]  Magri, V., Trinchieri, A., Montanari, E., Del Nero, A., Mangiarotti, B., Zirpoli, P., de Eguileor, M., Marras, E., Ceriani, I., Vral, A., Perletti, G., “Prostatic diseases and male voiding dysfunction: Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy” Urology, 2010, 76, 436-41.
 
[9]  Irani, J., “Are all alpha-blockers created the same?” Eur Urol 2006, 49, 420-2.
 
[10]  Schilit, S., Benzeroual, K.E., “Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.” Clin Ther 2009, 31, 2489-502.
 
[11]  Rossitto, G., Kamath, G., Messerli, F.H., “Should alpha-blockers ever be used as antihypertensive drugs?” Cleve Clin J Med, 2010, 77(12), 884-888.
 
[12]  European Pharmacopoeia. European Directorate for the Quality of Medicines. Strasbourg, 2007.
 
[13]  USP29–NF24, Pharmacopeial Forum : Volume No. 29(5) Page 1580.
 
[14]  Terazosin hydrochloride dehydrate. British Pharmacopoeia. 2012. Available online http://bp2012.infostar.com.cn/Bp2012.aspx?a=query&title=%22Terazosin+Hydrochloride+Dihydrate%22&tab=a-z+index&l=T&xh=1. Assessed in 15/08/2013.
 
[15]  National Formulary of India (NFI), 4th Edition, Indian Pharmacopoeia Commission. Ministry of Health & Family Welfare, Government of India.2011, pp 314.
 
[16]  Attia, A.K., Abdel-Moety, M.M., “Thermoanalytical Investigation of Terazosin Hydrochloride”. Advanced Pharm. Bull., 2013, 3(1), 147-152. doi: http://dx.doi.org/10.5681/apb.2013.025.
 
[17]  Anthony, C.M., Osselton, M.D., Widdop, B. Clark's Analysis of Drugs and Poisons. 3rd ed. London: Pharmaceutical Press;2004.
 
[18]  Low, B.Y., Liong, M.L., Yuen, K.H., Chee, C., Chong, W.L., Khan, N.A., Cheah, P.Y., Liong, K.K., “Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.” J Urol, 2008, Apr; 179(4), 1461-9.
 
[19]  Vinnakota, S., Aluru Raghavendra, G.P., Kakarla, R.K., Vahi, S., Lakshmana Rao, K., Rao R. “A new spectrophotometric method for the determination of trace amounts of titanium(IV)” Facta Universitatis. Physics, Chemistry and Technology, 2010, 8(1), 15-24.
 
[20]  Jamaluddin Ahmed, M., Zannat, T. “A simple spectrophotometric method for the determination of copper in some real, environmental, biological, food and soil samples using salicylaldehyde benzoyl hydrazone” Pak. J. Anal. Environ. Chem. 2012, 13(1), 22-35.
 
[21]  Morawski, R.Z., “Measurement data processing in spectrophotometric analysers of food.” Metrol Meas Syst, 2012, 19(4), 623-652.
 
[22]  Marczenko, Z., Balcerzak, M. “Separation, Preconcentration and Spectrophotometry in Inorganic Analysis”. Elsevier, First edition, 2000, pp. 26.
 
[23]  Bosch Ojeda, C., Sanchez Rojas, F. “Recent applications in derivative ultraviolet/visible absorption spectrophotometry: 2009-2011. A Review.” Microchem J, 2013, 106, 1-16.
 
[24]  Sankar, V., Raghuraman, S., Sivanand, V., Ravichandran, V., “Spectrophotometric method for the estimation of Terazosin in Tablets.” Ind J Pharm Sci, 2000, 61(6): 463-464.
 
[25]  Prasad, C.V.N., Gautham, A., Bhardwaj, V., Praimoo, P. “Quantitative determination of Terazosin HCl in tablet preparation by fluorimetry”. Ind J Pharm Sci, 1998, 60(3), 167-9.
 
[26]  Zeeb, M., Sadeghi, M., “Sensitive Determination of Terazosin in Pharmaceutical Formulations and Biological Samples by Ionic-Liquid Microextraction Prior to Spectrofluorimetry.” Inter J Anal Chem 2012, 1-7.
 
[27]  Jiang, C.J., Gao, M.X., He, J.X., “Study of the interaction between terazosin and serum albumin synchronous fluorescence determination of terazosin.” Anal Chim Acta, 2002, 452, 185-189.
 
[28]  Wang, C.C., Luconi, M.O., Masi, A.N., Fernández, L., “Determination of terazosin by cloud point extraction-fluorimetric combined methodology.” Talanta, 2007, 72(5), 1779-85.
 
[29]  Abdine, H.H., El-Yazbi, F.A., Blaih, S.M., Shaalan, R.A., “Spectrophotometric and spectrofluorimetric methods for the determination of terazosin in dosage forms.” Spectrosc Lett: Int J Rapid Communication, 1998, 31(5), 969-980.
 
[30]  El Sheikh, R., Esmail, N.S., Gouda, A.A., Basset, W.A., “Extractive spectrophotometric determination of some α-adrenergic antagonists in pure forms and in pharmaceutical formulations.” CI & CEQ, 2012, 18(2), 179-191.
 
[31]  Shrivastava, A., Gupta, V.B., “Ultra violet spectrophotometric method: Not possible for the simultaneous estimation of alpha one adrenoreceptor blockers.” J Pharm Negative Results, 2011, 2, 115-120.
 
[32]  Silva, R.A., Masi, A.N., “Sensitive determination of terazosin by x-ray fluorescence spectrometry based on the formation of ion-pair associates with zinc thiocyanate.” X-Ray Spectrom, 2007, 36, 279-283.
 
[33]  Nahata A., Spectrofluorimetry as an Analytical Tool. Pharm Anal Acta, 2011, 2, 107e.
 
[34]  Darwish, I.A., Amer, S.M., Abdine, H.H., Al-Rayes, L.I., “New spectrofluorimetric method with enhanced sensitivity for determination of paroxetine in dosage forms and plasma.” Anal Chem Insights 2008, 3, 145-155.
 
[35]  Shrivastava, A., Saxena, P., Gupta, V.B. “Spectrophotometric estimation of tamsulosin hydrochloride by acid-dye method” Pharm Methods 2011, 2, 53-60.
 
[36]  Wixom, R.L., Gehrke, C.W., Berezkin, V.G., Janak, J. “Chromatography a new discipline of science.” In: Chromatography: A Science of Discovery. Editor: Robert L. Wixom, Charles W. Gehrke. John whiley and sons, 2010, pp. 5, 12.
 
[37]  Miller, J.M., “Chromatography: Concepts and Contrasts.” John whiley and sons, 2005. pp.1.
 
[38]  Shrivastava, A., Gupta, V.B., “HPLC: Isocratic or Gradient Elution and Assessment of Linearity in Analytical Methods.” J Adv Scient Res, 2012, 3(2), 12-20.
 
[39]  Validation of chromatographic methods. Reviewer guidance. Center for Drug Evaluation and Research (CDER). 1994.
 
[40]  Jain, S.K., Soni, V., “Bentley's Textbook of Pharmaceutics.” Benteleys textbook of pharmaceutics. Elsevier, 2012.
 
[41]  Srivastava, M.M., “High-Performance Thin-Layer Chromatography (HPTLC).” Springer Heidelberg Dordrecht London New York, 2011, pp 9.
 
[42]  Chang Zui, L., Bauer, J.F. “Analytical Profile of Drug Substances”, 20th volume, Academic Press, Elsevier; 2005, 717-720.
 
[43]  Shrivastava, A., Patel, A., Gupta, V.B., “Stability Indicating HPTLC Determination of Terazosin in Tablet Formulation, World J Anal Chem, 2013, 1(3), 31-36.
 
[44]  Shrivastava, A., Gupta, V.B., “Validated HPLC and HPTLC Methods for Simultaneous Determination of Some α1-Adrenoreceptor Blockers.” Lat Am J Pharm, 2012, 31(2), 279-86.
 
[45]  Taguchi, K., Scha¨fers, R.F., Michel, M.C., “Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.” Br J Clin Pharmacol, 1998, 45, 49-55.
 
[46]  Cheah PY, Yuena KH, Liong ML. Improved high performance liquid chromatographic analysis of terazosin in human plasma. J Chromatogr B, 2000, 745, 439-443.
 
[47]  Zavitsanos, A.P., Alebic-Kolbah, T., “Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography–electrospray mass spectrometry.” J Chromatogr A, 1998, 794, 45-56.
 
[48]  Zou, H.Y., Wu, H.L., OuYang, L.Q., Zhang, Y., Nie, J.F., Fu, H.Y., Yu RQ., “Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition.” Analy Chim Acta, 2009, 650, 143-149.
 
[49]  Bauer, J.F., Krogh, S.K, Chang, Z.L., Wong, C.F., “Determination of minor impurities in terazosin by high performance liquid chromatography.” J Chromatography, 1993, 648, 175-181.
 
[50]  Bakshi, M., Ojha, T., Singh, S., “Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.” J Pharm Biomed Anal 2004, 34, 19-2.
 
[51]  Ojha, T., Bakshi, M., Chakraborti, A.K., Singh, S., “The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour.” J Pharm Biomed Anal, 2003, 31, 775-783.
 
[52]  EY Oh, SK Bae, JW Kwon, M You, DC Lee, MG Lee. Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. Br J Clin Pharmacol, 2007, 151, 24-34.
 
[53]  Wei, X., Yin, J., Yang, G., He, C., Chen, Y., “On-line solid-phase extraction with a monolithic weak cation-exchange column and simultaneous screening of α1-adrenergic receptor antagonists in human plasma. J Sep Sci, 2007, 30, 2851-2857.
 
[54]  Chen, D., Zhao, C., “Determination of Terazosin in Human Plasma by High performance Liquid Chromatography with Ultraviolet Detection.” Asian J Traditional Med. 1-3.
 
[55]  Shrivastava, A., Gupta, V.B., “Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations.” Sci Pharm, 2012, 80, 619-631.
 
[56]  Shrivastava, A., Gupta, V.B., “Simultaneous Determination of Two Alpha-One Adrenoreceptor Blockers Terazosin and Prazosin Using Tamsulosin as Internal Standard.” Inter J Pharm Pharma Sci, 2012, 4(3), 752-756.
 
[57]  Papadoyannisa, I.N., Zotou, A., “Fluorescence Detection in HPLC. Encyclopedia of Chromatography.” Third Edition. 2009.
 
[58]  Khalil, N.Y., Darwish, I.A., Wani, T.A., Al-Majed, A.R., “Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.” Chem Cent J, 2013, 7, 52.
 
[59]  Shrivastava, A., “Analytical methods for venlaflaxine hydrochloride and metabolites determinations in different matrices.” Syst Rev Pharm 2012, 3, 42-50.
 
[60]  Shrivastava, A., Sharma, J., Soni, V., “Various electroanalytical methods for the determination of uranium in different matrices.” B-FOPCU, 2013, 51, 113-129.
 
[61]  Dogan-Topal, B., Ozkan, S.A., Uslu, B., “The analytical applications of square wave voltammetry on pharmaceutical analysis.” Open Chem Biomed Met J, 2010, 3, 56-73.
 
[62]  Badawey, A.M., Abd El-Aleem, A.E.B., Lamie, N.T., “Membrane sensors for the selective determination of terazosin hydrochloride dihydrate in presence of its degradation product.” Inter J Comp Pharm, 2011, 2(7), 1-5.
 
[63]  Ganjali, M.R., Faridbod, F., Larijani, B., Riahi, S., Hosseini, M., Nasli-Esfahani, E et al. Terazosin potentiometric sensor for quantitative analysis of terazosin hydrochloride in pharmaceutical formulation based on computational study. Int. J. Electrochem. Sci., 2010, 5, 200-214.
 
[64]  Atta, N.F., Darwish, S.A., Khalil, S.E., Galal, A. “Effect of surfactants on the voltammetric response and determination of an antihypertensive drug.” Talanta 2007, 72, 1438-1445.